Home » Pipeline
Pipeline
February 1, 2021
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| OncoSec Medical | CORVax12 | COVID-19 vaccine | first patients dosed in phase 1 trial |
| Medigen Vaccine Biologics Dynavax |
MVC-COV1901 | COVID-19 vaccine | first patient dosed in phase 2 trial |
| VBL Therapeutics | VB-201 | patients with severe COVID-19 | first patient dosed in phase 2 trial |
| Other Trials and Actions | |||
| Organicell Regenerative Medicine | Zofin | chronic obstructive pulmonary disease | IND approved by the FDA |
| Passage Bio | PBFT02 | frontotemporal dementia with granulin mutations | IND approved by the FDA |
| Teneobio | TNB-585 | metastatic castrate-resistant prostate cancer | IND approved by the FDA |
| Cardiff Oncology | onvansertib | metastatic pancreatic ductal adenocarcinoma | IND approved by the FDA |
| Eucure Biopharma | YH001 | advanced solid tumors | first patient enrolled in phase 1 trial in China |
| Eyepoint Pharmaceuticals | EYP-1901 | wet age-related macular degeneration | first patient dosed in phase 1 trial |
| I-Mab Morphosys |
TJ210/MOR210 | relapsed or refractory advanced solid tumors | first patient dosed in phase 1 trial |
| Exelixis | XL102 | inoperable locally advanced or metastatic solid tumors | initiation of phase 1 trial |
| Zymeworks | ZW49 | heavily pretreated HER2 positive cancers | first patients enrolled in expansion cohort portion of phase 1 trial |
| Antios Therapeutics | ATI-2173 | chronic hepatitis B virus infection | completion of phase 1b trial |
| BioInvent | BI-1808 monotherapy and in combination with Keytruda (pembrolizumab) | solid tumors and cutaneous T-cell lymphoma | first patient enrolled in phase I/2a trial |
| Medicure | long-term use of Aggrastat (tirofiban hydrochloride) injection | aneurysmal subarachnoid hemorrhage | completion of phase 1/2a trial |
| Ayala Pharmaceuticals | AL101 | notch-activated recurrent or metastatic triple negative breast cancer | first patient dosed in phase 2 trial |
| Meissa Vaccines | MV-012-968, intranasal live attenuated vaccine | respiratory syncytial virus | first patients dosed in phase 2 trial |
| Surface Ophthalmics | SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) | chronic dry eye disease | first patient dosed in phase 2 trial |
| DURECT | DUR-928 | severe alcohol-associated hepatitis | first patient dosed in phase 2b trial |
| SFJ Pharmaceuticals PhaseBio |
bentracimab | reversal of antiplatelet effects of Brilinta (ticagrelor) | first patient dosed in EU in phase 3 trial |
| Marinus Pharmaceuticals | IV ganaxolone | refractory status epilepticus | first patient enrolled in phase 3 trial |
| Prilenia Therapeutics | pridopidine | early-stage Huntington’s disease | first patient enrolled in Europe in phase 3 trial |
| Quantum Genomics | firibastat | treatment-resistant hypertension | initiation of phase 3 trial |
| Telix Pharmaceuticals | TLX250-CDx (89Zr-girentuximab), renal cancer diagnostic imaging agent | noninvasive detection of clear-cell renal cell carcinoma | first patients dosed in phase 3 trial |
| M6P Therapeutics | four recombinant enzyme and two gene therapy programs | lysosomal storage disorders | Rare Pediatric Disease designations granted by the FDA |
| M6P Therapeutics | two gene therapy programs | Gaucher disease and mucolipidosis | Orphan Drug designations granted by the FDA |
| Q BioMed | Uttroside-B | hepatocellular carcinoma | Orphan Drug designation granted by the FDA |
| Veralox Therapeutics | VLX-1005 | heparin-induced thrombocytopenia | Orphan Drug designation granted by the FDA |
| Junshi Biosciences | toripalimab | first-line treatment of mucosal melanoma | Fast-Track designation granted by the FDA |
| PEDRA Technology | PEDRA Xauron Perfusion System | critical limb-threatening ischemia | Breakthrough Device designation granted by the FDA |
| Merck KGaA Pfizer |
Bavencio (avelumab) | first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy | approved by the European Commission for expanded indication |
| Aurinia Pharmaceuticals | Lupkynis (voclosporin) in combination with background immunosuppressive therapy | adults with active lupus nephritis | approved by the FDA |
| Boston Scientific | Vercise Genus Deep Brain Stimulation System | deep-brain stimulation in patients with Parkinson's disease | approved by the FDA |
| Exelixis | Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) | first-line treatment of advanced renal cell carcinoma | approved by the FDA |
| OrthoSpin | Generation 2 OrthoSpin system | external fixation system for orthopedic treatments | approved by the FDA |
| Recordati Rare Diseases | Carbaglu (carglumic acid) tablets 200mg | adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia or methylmalonic acidemia in children and adults | approved by the FDA for new indication |
| Theranica | Nerivio therapeutic device | acute treatment of episodic or chronic migraine in people 12 years and older | approved by the FDA for expanded indication |
| ViiV Healthcare | Cabenuva (rilpivirine and cabotegravir) | HIV | approved by the FDA |
Upcoming Events
-
28Sep
-
18Oct
